Viscosity is one major challenge in manufacturing and formulating highly concentrated antibody drug products suitable for subcutaneous injection. Especially during concentration steps in downstream processing, attractive interactions and resulting high viscosity bear challenges that can limit the maximum protein concentration. The selection of suitable tangential flow filtration (TFF) cassettes, paired with the Viscosity Reduction Platform, consisting of viscosity-modifying excipient combinations that provide a tailored solution to address viscosity issues, enables significantly higher target protein concentrations with improved processing economics.
In this webinar, you will learn:
- Challenges arising from highly concentrated protein solutions during formulation by TFF
- The impact of TFF cassette design
- Benefits of viscosity-reducing excipient combination during TFF
Speakers
Tobias Rosenkranz, Ph.D.
Merck
Senior Manager, Biomolecule Formulation R&D
Tobias Rosenkranz heads the biomolecule formulation team in the liquid formulation R&D department in Darmstadt. His lab mainly focuses on formulation challenges arising in protein formulations, such as protein viscosity and aggregation. A biophysicist by training, he holds a Ph.D. from the HHU Düsseldorf/Research Centre Jülich. Prior to joining the company in 2017, Tobias was a basic researcher at UIUC (US) and UNSW Australia.
Gerd Walter
Merck
Director, Customer Application, Downstream, EMEA
Gerd Walter is a director in customer application, downstream, with more than 25 years of experience. He has a wide range of biotech knowledge on mAbs, recombinant proteins, vaccines, VGT, plasma, classical pharma, as well as cGMP understanding from upstream to downstream and final filling.
Pharma and biopharma manufacturing
- Liquid Formulation Strategies
期間:40min
言語:English
セッション 1:presented May 19, 2022
続きを確認するには、ログインするか、新規登録が必要です。
アカウントをお持ちではありませんか？